SNDL公布2026年Q3业绩：调整后经营利润转正、自由现金流创纪录，但计提5200万加元商誉减值且大麻生产板块收入下滑27.7%

----- f6k_102726.htm -----
6-K
1
f6k_102726.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number:
001-39005
SNDL Inc.
(Translation of registrant's name into English)
#101, 17220 Stony Plain Road NW
Edmonton, AB T5S 1K6
Tel.: (780) 944-9994
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SNDL Inc.
(Registrant)
Date: October 27, 2026
/s/ Alberto Paredero Quiros
Alberto Paredero Quiros
Chief Financial Officer
EXHIBIT INDEX
Exhibit Number
Description
99.1
Press Release dated October 27, 2026

----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
SNDL Reports Third Quarter 2026 Financial and Operational Results
The Company Makes Significant Strategic Investments While Improving Underlying Financial Performance and Generating Record Quarterly Free Cash Flow of $20 Million
EDMONTON, Alberta, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ/CSE: SNDL) (“
SNDL
” or the “
Company
”) reported its financial and operational results for the third quarter ended September 30, 2026. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.
SNDL has also posted a supplemental investor presentation on its website, found at
https://sndl.com
.
The Company will hold a
conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026.
The conference call details can be found below.
MANAGEMENT HIGHLIGHTS
Net revenue
for the third quarter of 2026 was $238.0 million, representing a -2.5% decrease compared with the same period of the prior year. Cannabis Retail revenue increased by 0.7%, while Liquor Retail and Cannabis Operations revenue declined by -3.3% and -27.7%, respectively.
Gross profit
of $57.9 million for the third quarter of 2026 represents a decline of $(6.3) million, or -9.8%, compared with the same period of the prior year.
Gross margin
(1)
was 24.3% in the third quarter of 2026, a decrease of 2.0 percentage points compared with the same period of the prior year, primarily reflecting weak performance of Cannabis Operations. Both retail segments delivered strong margin expansion and reached new quarterly records.
Operating loss
was $(48.3) million for the third quarter of 2026, reflecting a $52 million non-cash goodwill impairment charge related to the Cannabis Operations segment.
Adj. operating income
(1)
, which excludes impairment charges and restructuring costs, returned to positive territory at $5.2 million, an improvement of $14.8 million compared with the same period of the prior year.
Cash flow
was $(50.7) million, reflecting $60.8 million of strategic investments in the U.S. and $10.0 million of additional share repurchases, consistent with our capital allocation priorities.
Free cash flow
(1)
reached a new quarterly record of $20.0 million in the third quarter of 2026, an increase of $3.3 million, or 19.5%, compared with the same period of the prior year, including a $10.6 million benefit associated with the initial unwinding of the Company’s captive insurance arrangement.
“Our third quarter results demonstrate improvement in SNDL’s underlying financial performance, including positive adjusted operating income and record quarterly free cash flow generation,” said Zach George, Chief Executive Officer of SNDL. “Cannabis Retail delivered record quarterly revenue and gross margin, Liquor Retail also reached a new record quarterly gross margin, and our Investments segment benefited from improved results from equity-accounted investees.”
“Cannabis Operations remained below expectations and recorded a non-cash impairment. While the quarter was impacted by inventory issues arising from the first half, we are taking decisive action to simplify the portfolio, reduce costs and concentrate resources on product categories where SNDL’s manufacturing capabilities, distribution reach and retail insights can support sustainable returns. The benefits of the actions taken during the quarter are expected to begin contributing to results in the fourth quarter. In addition to these immediate actions, the Company is initiating a strategic review of the Cannabis Operations segment to assess opportunities to improve its financial performance. The review will consider a range of strategic and operational alternatives, from potential asset divestitures to larger productivity initiatives.”
“The completion of the restructuring of Surterra Holdings, Inc. (“Parallel”) in July of this year, which reduced its debt burden by approximately US$842 million, and the subsequent rights offering, which increased our indirect equity ownership from approximately 67% to 92%, represent important steps in resetting Parallel’s capital structure and providing liquidity to support inventory, product availability and critical supply-chain infrastructure. SNDL-funded investments by SunStream Bancorp Inc. (“SunStream”) in a new cultivation facility in Gainesville, Florida, are expected to enhance Parallel’s cost structure. We are excited by the opportunity presented by our investment in Parallel and are actively exploring the feasibility of transitioning our indirect economic exposure to direct ownership and consolidation of qualifying U.S. medical cannabis operations, subject to applicable legal, regulatory, accounting and Nasdaq requirements.”
“We are encouraged by the progress made toward resolving the regulatory matters involving the Alcohol and Gaming Commission of Ontario (“AGCO”), which we expect will provide greater clarity for the Ontario franchise retail operations and future development opportunities, as further detailed later in this document and in the Q3 2026 Earnings Call presentation.”
“Across SNDL, our priorities remain disciplined capital allocation, improved operating performance and long-term value creation for shareholders. We have demonstrated that commitment through significant share repurchases, and we intend to remain aggressive when we believe the opportunity to acquire our shares represents an attractive use of capital. The recently announced potential $50 million substantial issuer bid (“SIB”) is a further step toward accelerating capital returns and reducing our outstanding share count,” concluded Zach George.
TOTAL COMPANY HIGHLIGHTS
Three months ended September 30
Nine months ended September 30
($000s)
2026
2025
% Change
2026
2025
% Change
IFRS Financial Measures
Net revenue
237,994
244,219
-2.5
%
669,666
693,902
-3.5
%
Gross profit
57,886
64,177
-9.8
%
167,047
188,419
-11.3
%
Operating income (loss)
(48,317
)
(11,050
)
-337.3
%
(65,272
)
(18,100
)
-260.6
%
Change in cash and cash equivalents
(50,729
)
32,357
-256.8
%
(107,622
)
22,222
-584.3
%
Non-IFRS Financial Measures
(1)
Gross margin
24.3
%
26.3
%
-2.0
pp
24.9
%
27.2
%
-2.2
pp
Adjusted operating income (loss)
5,249
(9,512
)
155.2
%
(10,675
)
(12,713
)
16.0
%
Free cash flow
19,954
16,692
19.5
%
5,692
7,733
-26.4
%
(1)   Gross Margin is a supplementary financial measure calculated by dividing Gross Profit by Net Revenue. Adjusted operating income (loss) and Free Cash Flow are specified financial measures that do not have standardized meanings under IFRS and therefore may not be comparable to similar measures reported by other companies. See “Non-IFRS Measures” section below for further information.
BUSINESS SEGMENT HIGHLIGHTS
SNDL operates and reports its business through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. Additionally, a consolidated total for Cannabis is presented, encompassing the combined results of the two Cannabis segments, along with the revenue elimination associated with the Cannabis Operations sales to the provincial boards that are expected to be subsequently repurchased by the Company’s licensed retail subsidiaries for resale. Corporate and shared service expenses are reported as “Corporate”.
Three months ended September 30
Nine months ended September 30
($000s)
2026
2025
(2)
% Change
2026
2025
(2)
% Change
Net Revenue
Cannabis Retail
85,605
85,021
0.7
%
246,154
246,960
-0.3
%
Cannabis Operations
27,040
37,389
-27.7
%
88,704
107,544
-17.5
%
Intersegment Eliminations
(9,425
)
(17,579
)
46.4
%
(38,757
)
(51,391
)
24.6
%
Total Cannabis
103,220
104,831
-1.5
%
296,101
303,113
-2.3
%
Liquor Retail
134,774
139,388
-3.3
%
373,565
390,789
-4.4
%
Investments
—
—
0.0
%
—
—
0.0
%
Total
237,994
244,219
-2.5
%
669,666
693,902
-3.5
%
Operating Income
Cannabis Retail
5,244
5,047
3.9
%
9,328
10,557
-11.6
%
Cannabis Operations
(64,693
)
(10,882
)
-494.5
%
(80,836
)
(20,186
)
-300.5
%
Total Cannabis
(59,449
)
(5,835
)
-918.8
%
(71,508
)
(9,629
)
-642.6
%
Liquor Retail
6,035
6,591
-8.4
%
5,899
10,884
-45.8
%
Investments
7,861
1,543
409.5
%
8,340
1,775
369.9
%
Corporate
(2,764
)
(13,349
)
79.3
%
(8,003
)
(21,130
)
62.1
%
Total
(48,317
)
(11,050
)
-337.3
%
(65,272
)
(18,100
)
-260.6
%
Adjusted Operating Income
Cannabis Retail
5,284
5,047
4.7
%
9,403
10,557
-10.9
%
Cannabis Operations
(11,391
)
(10,220
)
-11.5
%
(27,303
)
(16,258
)
-67.9
%
Total Cannabis
(6,107
)
(5,173
)
-18.1
%
(17,900
)
(5,701
)
-214.0
%
Liquor Retail
6,037
6,591
-8.4
%
6,126
10,884
-43.7
%
Investments
7,861
1,543
409.5
%
8,340
1,775
369.9
%
Corporate
(2,542
)
(12,473
)
79.6
%
(7,241
)
(19,671
)
63.2
%
Total
5,249
(9,512
)
155.2
%
(10,675
)
(12,713
)
16.0
%
(2)   In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period, as documented in the condensed interim Financial Statements.
Liquor Retail
SNDL is Canada's largest private-sector liquor retailer, operating as of October 26, 2026 in 165 locations, predominantly in Alberta, under its three retail banners: “Wine and Beyond” (16), “Liquor Depot” (19), and “Ace Liquor” (130).
Three months ended September 30
Nine months ended September 30
($000s)
2026
2025
% Change
2026
2025
% Change
Net revenue
134,774
139,388
-3.3
%
373,565
390,789
-4.4
%
Gross profit
36,390
36,704
-0.9
%
96,828
100,993
-4.1
%
Gross margin
27.0
%
26.3
%
0.7
pp
25.9
%
25.8
%
0.1
pp
Operating income
6,035
6,591
-8.4
%
5,899
10,884
-45.8
%
Adjusted operating income
6,037
6,591
-8.4
%
6,126
10,884
-43.7
%
Net revenue for Liquor Retail continued to decline year over year in the third quarter of 2026, although at a slightly better rate than in previous quarters. Persistent softness in market demand continued to affect same-store sales
(
3
)
, which decreased by -6.0% compared with the same period in the prior year.
Operating income declined year over year, driven by lower revenue, increased promotional support, and higher SG&A expenses associated with the recent Wine & Beyond store openings, partly offset by strong gross margin expansion, which reached a new quarterly record.
(3)   Same-store sales is a specified financial measure that does not have standardized meanings under IFRS and therefore may not be comparable to similar measures used by other companies. See “Non-IFRS Measures” section below for further information.
Cannabis Retail
SNDL is one of Canada’s largest private-sector cannabis retailers, operating as of October 26, 2026 in 193 locations under two retail banners: “Value Buds” (133) and “Spiritleaf” (60, of which 4 are corporate stores and 56 are franchise stores). The Company’s Cannabis Retail strategy is based on several pillars, including high-quality store locations, a broad product assortment and differentiated customer experiences. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.
Three months ended September 30
Nine months ended September 30
($000s)
2026
2025
% Change
2026
2025
% Change
Net revenue
85,605
85,021
0.7
%
246,154
246,960
-0.3
%
Gross profit
23,118
22,465
2.9
%
65,472
63,974
2.3
%
Gross margin
27.0
%
26.4
%
0.6
pp
26.6
%
25.9
%
0.7
pp
Operating income
5,244
5,047
3.9
%
9,328
10,557
-11.6
%
Adjusted operating income
5,284
5,047
4.7
%
9,403
10,557
-10.9
%
Net revenue for Cannabis Retail returned to growth in the third quarter compared with the same period of the prior year, consistent with the previously anticipated inflection point, and reached a new quarterly record. Market contraction in our largest provinces (ON, AB) contributed to a -3.8% decline in same-store sales. This decline was partially offset by incremental revenue from new stores and Value Buds store conversions.
Operating income increased compared with the same period of the prior year, primarily driven by gross margin expansion, which reached a new quarterly record, despite lapping a larger impairment reversal recorded in the third quarter of 2025.
Subject to completion of definitive documentation and payment of a $200,000 monetary penalty, the anticipated resolution of the regulatory matters involving the AGCO is expected to allow the Value Buds franchise network to resume growth in Ontario following a pause of more than a year during the regulatory review. While the contemplated structure is expected to result in the deconsolidation of the Ontario retail operations from SNDL’s financial statements, we expect the overall commercial arrangements to substantially preserve SNDL’s net economics associated with these franchise locations, without retaining control over the retail operations in the province.
Cannabis Operations
SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL’s vertical integration strategy.
Three months ended September 30
Nine months ended September 30
($000s)
2026
2025
% Change
2026
2025
% Change
Net revenue
27,040
37,389
-27.7
%
88,704
107,544
-17.5
%
Gross profit
(1,622
)
5,008
-132.4
%
4,747
23,452
-79.8
%
Gross margin
-6.0
%
13.4
%
-19.4
pp
5.4
%
21.8
%
-16.5
pp
Operating income (loss)
(64,693
)
(10,882
)
-494.5
%
(80,836
)
(20,186
)
-300.5
%
Adjusted operating income (loss)
(11,391
)
(10,220
)
-11.5
%
(27,303
)
(16,258
)
-67.9
%
Our Cannabis Operations results remain below our expectations, and we are moving aggressively to reshape the segment into a more focused and efficient business. Most of the revenue decline in the third quarter was attributable to our exit from the unprofitable domestic dried flower category and our increased focus on higher-value products.
Profitability was impacted by a $52 million non-cash goodwill impairment reflecting current business trends, as well as $6 million in other impacts, mostly driven by inventory adjustments related to the exit from the dried flower category and Jeeter cost variances. During the third quarter, we took decisive actions to reduce manufacturing costs and other operating expenses, particularly at our Kelowna manufacturing facility, including a reduction of more than 30% of the workforce at the site. The P&L benefits of these cost reductions are expected to begin contributing to results in the fourth quarter.
Investments
As of September 30, 2026, the Company’s portfolio of cannabis-related investments had a carrying value of $485.2 million, including $467.7 million to SunStream Bancorp Inc. (“SunStream”). This carrying value was increased by $70.0 million during the third quarter of 2026, primarily driven by additional contributions to fund the buildout of the Gainesville, Florida cultivation facility, SNDL’s participation in Parallel’s rights offering, and the purchase of an incremental portion of Parallel’s debt.
On July 27, 2026, the restructuring of Parallel was completed, providing SNDL with indirect majority economic exposure to the company. During the third quarter, SNDL participated in a Parallel rights offering, while other minority holders declined to participate, increasing SNDL’s indirect equity interest from approximately 67% to approximately 92%. SNDL continues to evaluate a pathway to directly own and consolidate Parallel’s U.S. medical cannabis operations while maintaining compliance with the applicable Nasdaq requirements. Consistent with recent public-market precedents, SNDL is evaluating structures that distinguish medical cannabis operations from adult-use exposure, with the latter expected to remain outside SNDL’s consolidated operations. The Company is actively advancing this work and expects to provide further clarity as the structure and timing are finalized, subject to applicable legal, regulatory, accounting and Nasdaq requirements.
Following the completion of Parallel’s restructuring, SNDL also financed SunStream’s purchase of an additional portion of Parallel’s takeback debt at 75% of face value, increasing SunStream’s debt ownership from 39.4% to 69.4%.
The Investments segment generated $7.9 million of operating income during the third quarter of 2026, including $6.9 million from SNDL’s share of profit from SunStream’s equity-accounted investees, primarily reflecting an increase in the valuation of Parallel.
The previously disclosed restructuring process relating to Skymint continues. On April 1, 2026, the Michigan Supreme Court agreed to hear oral argument on applications for leave to appeal. The Court has not reached a decision on the merits. Timing and outcomes remain uncertain and are subject to court process and other factors.
On April 23, 2026, the United States Department of Justice and the United States Drug Enforcement Administration issued an order placing Food and Drug Administration-approved cannabis products and qualifying state-regulated medical cannabis in Schedule III of the United States Controlled Substances Act, while initiating an expedited administrative process to consider the broader rescheduling of cannabis, including adult-use cannabis, from Schedule I to Schedule III. The administrative hearing concluded in July 2026, with a final determination on broader rescheduling still pending.
Equity Position
$617.8 million of unrestricted cash, marketable securities and investments, including investments in equity-accounted investees, and no outstanding debt at September 30, 2026, resulting in a net book value of $1.0 billion.
During the third quarter of 2026, the Company purchased for cancellation 5,431,300 common shares at a weighted average price, excluding commissions, of US$1.31 per share. Year-to-date through October 22, 2026, the Company had purchased for cancellation 23,088,153 common shares, resulting in 243,320,644 common shares outstanding.
As recently communicated, the Company’s Board of Directors has directed management to pursue a possible substantial issuer bid (“SIB”) for an aggregate purchase price of up to C$50 million and at a price per share not exceeding C$1.92 (US$1.35). If completed and fully subscribed at the maximum price, the SIB could reduce the Company’s common shares outstanding by more than an additional 10%. SNDL will continue to evaluate opportunities to repurchase shares where management believes doing so is in the best interests of SNDL and its shareholders. In this context, and subject to approval by SNDL’s Board of Directors, we expect to proceed with the renewal of the share repurchase program upon its expiration on November 20, 2026, supported by continued free cash flow and potential targeted asset sales, including non-core real estate and other operating assets.
This press release is intended to be read in conjunction with the Company’s condensed consolidated interim financial statements and the notes thereto for the three and nine months ended September 30, 2026, and the accompanying Management’s Discussion and Analysis. These documents are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml.
CONFERENCE
CALL
The Company will hold a
conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026.
WEBCAST ACCESS
To access the live webcast of the call, please visit the following link:
https://edge.media-server.com/mmc/p/wcotys5n
REPLAY
A replay of the webcast will be available at
https://sndl.com/financials/quarterly-results/default.aspx
ABOUT SNDL INC.
SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. With products available in licensed cannabis retail locations nationally, SNDL’s consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit
www.sndl.com
For more information:
Tomas Bottger
Investor Relations, SNDL Inc.
O: 1.587.327.2017
E:
investors@sndl.com
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company’s operational goals, plans and key priorities, the strategic review of the Cannabis Operations segment, including its scope, potential alternatives and outcomes, and the expected benefits of any actions resulting from the review, the Company’s ability to deploy capital and the expected benefits thereof, expectations related to the Jeeter contract, the growth opportunities available to SNDL and the expected benefits thereof, expectations with respect to the 1CM transaction, including the satisfaction of certain regulatory approvals, the progress of the Sunstream restructurings, expectations with respect to the Skymint and Parallel restructuring processes, the feasibility, structure, timing and expectations related to the Company obtaining direct ownership and control of, and consolidating, qualifying U.S. medical cannabis operations of Parallel, SNDL’s corporate restructuring program, including the timing to conclude the restructuring and expected benefits thereof, the expected benefits of the enterprise resource planning (“ERP”) system consolidation, SNDL’s ability to recover the senior secured notes held in Cannabist, the timing and expected impact of reclassifying cannabis from Schedule I to Schedule III under the United States
Controlled Substances Act
, the Company’s retail strategy, and any other potential forms of shareholder value creation. Forward-looking statements are frequently characterized by words such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “due”, “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “pioneer”, “seek”, “should”, “target”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which it operates and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see “Risk Factors” in the Company’s annual information form dated March 11, 2026, and the risk factors included in our other public disclosure documents for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss
(Expressed in thousands of Canadian dollars, except per share amounts)
Three months ended
September 30
Nine months ended
September 30
2026
2025
2026
2025
Net revenue
237,994
244,219
669,666
693,902
Cost of sales
180,108
180,042
502,619
505,483
Gross profit
57,886
64,177
167,047
188,419
Investment income
927
1,777
3,472
6,162
Share of profit (loss) of equity-accounted investees
6,934
(234
)
5,084
(4,387
)
General and administrative
43,284
45,967
132,732
137,702
Sales and marketing
3,462
3,617
11,136
10,768
Depreciation and amortization
12,659
12,928
38,145
39,076
Share-based compensation
1,767
10,883
5,033
15,190
Restructuring costs
577
1,134
1,608
2,287
Asset impairment, net
52,331
2,051
52,151
2,971
Other income
—
—
(81
)
—
Research and development
—
156
12
354
(Gain) loss on disposition of assets
(16
)
34
139
(54
)
Operating loss
(48,317
)
(11,050
)
(65,272
)
(18,100
)
Other expenses, net
(2,464
)
(2,269
)
(6,424
)
(7,041
)
Loss before income tax
(50,781
)
(13,319
)
(71,696
)
(25,141
)
Income tax (expense) recovery
(8
)
—
3,174
—
Net loss
(50,789
)
(13,319
)
(68,522
)
(25,141
)
Equity-accounted investees - share of other comprehensive (loss) income
(29
)
7,709
10,625
(13,250
)
Investments at fair value through other comprehensive income ("FVOCI") - change in fair value
2,773
12,940
1,690
9,754
Comprehensive (loss) income
(48,045
)
7,330
(56,207
)
(28,637
)
Condensed Consolidated Interim Statement of Financial Position
(Expressed in thousands of Canadian dollars)
As at
September 30, 2026
December 31, 2025
Assets
Current assets
Cash and cash equivalents
132,479
252,243
Restricted cash
8,162
20,081
Marketable securities
139
84
Accounts receivable
31,734
27,643
Biological assets
2,407
3,120
Inventory
128,721
126,877
Prepaid expenses and deposits
16,614
15,566
Investments
106
484
Assets held for sale
700
746
Net investment in subleases
2,997
2,775
324,059
449,619
Non-current assets
Long-term deposits and receivables
2,457
4,526
Right of use assets
131,608
138,353
Property, plant and equipment
139,376
151,900
Net investment in subleases
9,954
11,643
Intangible assets
56,434
58,520
Investments
17,314
11,574
Equity-accounted investees
467,730
385,534
Goodwill
75,238
124,248
Total assets
1,224,170
1,335,917
Liabilities
Current liabilities
Accounts payable and accrued liabilities
46,902
56,747
Lease liabilities
35,706
35,462
82,608
92,209
Non-current liabilities
Lease liabilities
126,614
134,471
Other liabilities
7,753
8,041
Total liabilities
216,975
234,721
Shareholders’ equity
Share capital
2,127,355
2,310,398
Warrants
306
306
Contributed surplus
53,377
54,038
Accumulated deficit
(1,225,053
)
(1,302,441
)
Accumulated other comprehensive income ("AOCI")
51,210
38,895
Total shareholders’ equity
1,007,195
1,101,196
Total liabilities and shareholders’ equity
1,224,170
1,335,917
Condensed Consolidated Interim Statement of Cash Flows
(Expressed in thousands of Canadian dollars)
Three months ended
September 30
Nine months ended
September 30
2026
2025
2026
2025
Cash provided by (used in):
Operating activities
Net loss for the period
(50,789
)
(13,319
)
(68,522
)
(25,141
)
Adjustments for:
Income tax expense (recovery)
8
—
(3,174
)
—
Interest and fee income
(927
)
(1,675
)
(3,417
)
(5,849
)
Change in fair value of biological assets
585
180
594
(2,559
)
Change in fair value of inventory sold
(276
)
349
249
1,313
Share-based compensation
1,767
10,883
5,033
15,190
Depreciation and amortization
13,893
13,972
41,998
42,108
(Gain) loss on disposition of assets
(16
)
34
139
(54
)
Inventory impairment and obsolescence
3,455
1,833
6,057
2,663
Finance costs, net
1,951
1,812
6,007
5,149
Change in estimate of fair value of derivative warrants
—
(1
)
—
(26
)
Unrealized foreign exchange loss (gain)
180
(153
)
(832
)
40
Transaction costs
—
—
10
—
Asset impairment, net
52,331
2,051
52,151
2,971
Share of (profit) loss of equity-accounted investees
(6,934
)
234
(5,084
)
4,387
Unrealized (gain) on marketable securities
—
(102
)
(55
)
(313
)
Additions to marketable securities
—
—
151
313
Income distributions from equity-accounted investees
315
—
315
68
Interest received
822
1,409
3,377
5,628
Exercise of cash-settled deferred share units
—
—
(474
)
—
Change in non-cash working capital
2,185
14,194
(8,805
)
(282
)
Net cash provided by operating activities
18,550
31,701
25,718
45,606
Investing activities
Additions to property, plant and equipment
(1,196
)
(5,185
)
(5,620
)
(8,853
)
Additions to investments
—
—
(4,183
)
(16,414
)
Principal payments from investments
121
129
359
27,293
Proceeds from disposal of investments
—
15,058
—
15,058
Capital (contributions) distributions from equity-accounted investees
(60,762
)
481
(63,628
)
4,273
Proceeds from disposal of property, plant and equipment
538
—
2,332
166
Acquisitions
—
—
(2,900
)
(1,000
)
Change in non-cash working capital
75
39
712
10
Net cash (used in) provided by investing activities
(61,224
)
10,522
(72,928
)
20,533
Financing activities
Change in restricted cash
11,950
—
11,950
—
Payments on lease liabilities, net
(10,228
)
(9,920
)
(30,385
)
(29,217
)
Repurchase of common shares
(10,042
)
(3
)
(43,113
)
(15,034
)
Change in non-cash working capital
265
57
1,136
334
Net cash used in financing activities
(8,055
)
(9,866
)
(60,412
)
(43,917
)
Change in cash and cash equivalents
(50,729
)
32,357
(107,622
)
22,222
Adjustment on initial application of amendments to IFRS 9 on January 1, 2026
—
—
(12,142
)
—
Cash and cash equivalents, beginning of period
183,208
208,224
252,243
218,359
Cash and cash equivalents, end of period
132,479
240,581
132,479
240,581
NON-IFRS MEASURES
Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company’s operating results in the same manner as the management team.
ADJUSTED OPERATING INCOME (LOSS)
Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.
The following tables reconcile adjusted to un-adjusted operating income (loss) for the periods noted.
($000s)
Cannabis
Retail
Cannabis
Operations
Cannabis
Total
Liquor
Retail
Investments
Corporate
Total
Three months ended September 30, 2026
Operating income (loss)
5,244
(64,693
)
(59,449
)
6,035
7,861
(2,764
)
(48,317
)
Adjustments:
Restructuring costs
40
313
353
2
—
222
577
Goodwill and intangible asset impairments
—
52,022
52,022
—
—
—
52,022
Impairments triggered by restructuring
—
967
967
—
—
—
967
Adjusted operating income (loss)
5,284
(11,391
)
(6,107
)
6,037
7,861
(2,542
)
5,249
($000s)
Cannabis
Retail
Cannabis
Operations
Cannabis
Total
Liquor
Retail
Investments
Corporate
Total
Nine months ended September 30, 2026
Operating income (loss)
9,328
(80,836
)
(71,508
)
5,899
8,340
(8,003
)
(65,272
)
Adjustments:
Restructuring costs
75
544
619
227
—
762
1,608
Goodwill and intangible asset impairments
—
52,022
52,022
—
—
—
52,022
Impairments triggered by restructuring
—
967
967
—
—
—
967
Adjusted operating income (loss)
9,403
(27,303
)
(17,900
)
6,126
8,340
(7,241
)
(10,675
)
($000s)
Cannabis
Retail
Cannabis
Operations
Cannabis
Total
Liquor
Retail
Investments
Corporate
Total
Three months ended September 30, 2025
Operating income (loss)
(1)
5,047
(10,882
)
(5,835
)
6,591
1,543
(13,349
)
(11,050
)
Adjustments:
Restructuring costs
—
258
258
—
—
876
1,134
Impairments triggered by restructuring
—
404
404
—
—
—
404
Adjusted operating income (loss)
5,047
(10,220
)
(5,173
)
6,591
1,543
(12,473
)
(9,512
)
($000s)
Cannabis
Retail
Cannabis
Operations
Cannabis
Total
Liquor
Retail
Investments
Corporate
Total
Nine months ended September 30, 2025
Operating income (loss)
(1)
10,557
(20,186
)
(9,629
)
10,884
1,775
(21,130
)
(18,100
)
Adjustments:
Restructuring costs
—
828
828
—
—
1,459
2,287
Impairments triggered by restructuring
—
3,100
3,100
—
—
—
3,100
Adjusted operating income (loss)
10,557
(16,258
)
(5,701
)
10,884
1,775
(19,671
)
(12,713
)
(4)   In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.
GROSS MARGIN
Gross margin is a supplementary financial measure calculated as gross profit divided by net revenue for the periods presented. This measure evaluates the underlying profitability of our operations and provides useful information about the Company’s ability to price products effectively, manage input costs, drive operating efficiencies, and compare results across periods and business segments
FREE CASH FLOW
Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance, providing information which management believes to be useful in understanding and evaluating the Company’s ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).
The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.
Three months ended
September 30
Nine months ended
September 30
($000s)
2026
2025
2026
2025
Change in cash and cash equivalents
(50,729
)
32,357
(107,622
)
22,222
Adjustments:
Repurchase of common shares
10,042
3
43,113
15,034
Changes to long-term investments
60,641
(15,668
)
67,301
(30,523
)
Acquisitions, net of cash acquired
—
—
2,900
1,000
Free cash flow
19,954
16,692
5,692
7,733
SAME-STORE SALES
Same-store sales is a non-IFRS financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company’s sales trends excluding the effect of the opening and closure of stores.
Same store sales refers to the revenue generated by the Company’s existing retail locations during the current and prior comparison periods.
ADJUSTED EBITDA
Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company’s operating results. The Company defines adjusted EBITDA as net earnings (loss) before inventory and biological assets fair value and impairment adjustments, share of (gain) loss of equity-accounted investees, depreciation and amortization, share-based compensation expense, restructuring costs, asset impairment, gain or loss on disposal of property, other expenses, net, income tax expense (recovery) and excluding non-recurring items including ERP implementation costs and litigation settlements, net of recoveries.
Three months ended
September 30
Nine months ended
September 30
($000s)
2026
2025
2026
2025
Net earnings (loss)
(50,789
)
(13,319
)
(68,522
)
(25,141
)
Adjustments:
Inventory and biological assets fair value and impairment adjustments
3,764
2,362
6,900
1,417
Share of loss (profit) of equity-accounted investees
(6,934
)
234
(5,084
)
4,387
Depreciation and amortization
12,659
12,928
38,145
39,076
Share-based compensation
1,767
10,883
5,033
15,190
Restructuring costs
577
1,134
1,608
2,287
Asset (reversal) impairment
52,331
2,051
52,151
2,971
Loss (gain) on disposition of PP&E
(16
)
34
139
(54
)
Other expenses, net
2,464
2,269
6,424
7,041
Income tax recovery
8
—
(3,174
)
—
Non-recurring items
(15
)
(501
)
549
(696
)
Adjusted EBITDA
15,816
18,075
34,169
46,478